Frontiers in Oncology (Oct 2020)
Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma
- Hyunji Lee,
- Hyunji Lee,
- Minhee Kim,
- Minhee Kim,
- Seon-Hwan Kim,
- Quangdon Tran,
- Quangdon Tran,
- Gyeyeong Kong,
- Gyeyeong Kong,
- Chaeyeong Kim,
- Chaeyeong Kim,
- So Hee Kwon,
- Jisoo Park,
- Jisoo Park,
- Jisoo Park,
- Jin Bong Park,
- Jin Bong Park,
- Sungjin Park,
- Sungjin Park,
- Jongsun Park,
- Jongsun Park
Affiliations
- Hyunji Lee
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Hyunji Lee
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Minhee Kim
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Minhee Kim
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Seon-Hwan Kim
- Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Quangdon Tran
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Quangdon Tran
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Gyeyeong Kong
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Gyeyeong Kong
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Chaeyeong Kim
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Chaeyeong Kim
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- So Hee Kwon
- College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea
- Jisoo Park
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Jisoo Park
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Jisoo Park
- Department of Life Science, Hyehwa Liberal Arts College, LINC Plus Project Group, Daejeon University, Daejeon, South Korea
- Jin Bong Park
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Jin Bong Park
- Department of Physiology, College of Medicine, Chungnam National University, Daejeon, South Korea
- Sungjin Park
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Sungjin Park
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- Jongsun Park
- Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South Korea
- Jongsun Park
- Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, South Korea
- DOI
- https://doi.org/10.3389/fonc.2020.550673
- Journal volume & issue
-
Vol. 10
Abstract
Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.
Keywords
